info@PremierEndpoint.com (914) 315-9334
3 Ways AI Is Changing Medicine
September 21, 2017

Recent developments in artificial intelligence (AI) are turning science fiction into science fact — and deep learning is at the heart of these advances. These AI systems have the ability to sift through scores of data, recognize patterns, and detect differences that might be imperceptible to humans. Some applications are already achieving remarkable results. One […]

LISBON, PORTUGAL—Novo Nordisk’s combination med Xultophy, which marries its GLP-1 blockbuster Victoza and newest basal insulin Tresiba, became the latest diabetes med to show it could dampen risk factors for cardiovascular disease. The analysis, unveiled Wednesday at the European Association for the Study of Diabetes meeting in Lisbon, showed Xultophy patients had significantly lower systolic […]

– Data from this 12-week study showed that the safety and tolerability profile of Ofev® (nintedanib) with add-on pirfenidone is in keeping with the known profiles of the individual drugs in patients with IPF – Exploratory efficacy analyses suggest a potential benefit of the combination treatment of nintedanib with add-on pirfenidone – Results from INJOURNEY […]

THE HAGUE, The Netherlands, September 11, 2017 /PRNewswire/ — In the presence of former UN-Secretary-General Kofi Annan and Dutch minister Melanie Schultz of Infrastructure & the Environment, Micreos’ alternative to antibiotics was chosen as the most impactful innovation of The Netherlands. Micreos will represent The Netherlands at the semi-finals of Ideas from Europe in Talinn, Estonia […]

After winning an FDA approval for Exondys51 as a new therapy for Duchenne muscular dystrophy without having to actually produce data to prove it worked, Sarepta followed up this new morning with a fresh set of data from a small study underscoring the ability of its experimental followup exon-skipping drug golodirsen to trigger added production […]

Key FDA Regulatory Events to Watch Out for in Sep 2017
September 5, 2017

The FDA, which approved 22 novel drugs last year, has given its approval to 31 drugs so far in 2017 including five in August. Key approvals this year include Gilead’s Vosevi (hepatitis C virus), Puma’s Nerlynx (to reduce the risk of breast cancer returning), J&J’s Tremfya (moderate-to-severe plaque psoriasis), Regeneron/Sanofi’s Kevzara (rheumatoid arthritis), Roche’s multiple […]

Interesting article about Incyte Corporation stock from Dec 2016 which is still relevant: There aren’t too many biotechs around that are as hot as Incyte Corporation (NASDAQ:INCY) is right now. Incyte’s stock might be down a little year to date, but shares have surged since April. Can Incyte keep the momentum going in the new […]

PLAINSBORO, N.J., Aug. 25, 2017 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza® (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events, heart attack, stroke and CV death, in adults with type 2 diabetes and established CV disease. The FDA’s decision is based on the […]

1 2 3 16